Affinity Membranes Are Moving Closer To Commercial Reality

By Pengtao Gao and Xing Yang, KU Leuven

As biopharmaceutical pipelines expand to include a broad array of monoclonal antibodies and antibody-like molecules, viral vectors, and other complex biologics, downstream purification remains one of the most expensive and time-consuming parts of manufacturing. Traditional packed-bed chromatography has long been the industry standard, but it can be limited by slow diffusion, pressure constraints, and lengthy cycle times. Our recent review paper examines how advances in surface chemistry and ligand engineering are helping affinity membrane technology move from academic promise toward industrial reality.

Why Affinity Membranes Matter

Affinity membranes are attracting growing interest because they combine selective target recognition with the inherent flow advantages of membrane devices. This transport advantage can translate into higher productivity, shorter processing times, and greater operational flexibility, particularly when rapid capture and streamlined workflows are required. In biopharmaceutical manufacturing campaigns, affinity membrane adsorbers also provide practical benefits, including simplified installation, elimination of time-consuming column packing procedures and validation, reduced turnaround time between batches, and faster changeover across multiple products or production scales. These features make affinity membranes particularly attractive in manufacturing environments where speed, flexibility, and efficient facility utilization are increasingly important.

The Main Bottleneck: Surface Chemistry

While membrane adsorbers can provide rapid convective transport, adsorption performance ultimately depends on how effectively affinity ligands are introduced, distributed, and attached at the membrane interface. Poorly controlled surface reactions can lead to low ligand density, buried binding sites, heterogeneous coverage, and declining performance over repeated use.

Our review highlights that ligand immobilization is often constrained by competing reaction pathways and limited control over interfacial reactivity. Conventional approaches such as NHS/EDC coupling, epoxide reactions, nucleophilic substitution on triazine groups, and radical grafting can all be effective, but their outcomes are highly sensitive to the reaction environment, intermediate stability, water interference, and surface accessibility. As a result, membranes prepared using nominally similar chemistries may show markedly different capacities, reproducibility, and durability.

The challenge becomes even more important when one considers the need for cleaning/regeneration of the affinity membrane. Repeated regeneration with base or acid can gradually hydrolyze residual reactive groups, disrupt grafted interlayers, alter ligand presentation, or weaken the structural integrity of the modified surface. Even when the ligand itself remains attached, subtle chemical changes in the surrounding layer may reduce ligand accessibility and effective binding capacity over time.

This creates a clear direction for next-generation affinity membranes: move from empirical surface modification toward mechanistically designed coupling strategies that deliver predictable kinetics, selective bond formation, uniform ligand presentation, and robust long-term stability.

An especially promising approach is the use of pre-functionalized polymers, where reactive groups are incorporated into the material before membrane fabrication or final ligand attachment. Compared with post-fabrication surface treatment, these strategies can offer finer control over chemical composition, reactive-site density, and spatial distribution of functional groups, helping to produce more uniform and reproducible affinity interfaces. In practice, future platforms may combine pre-functionalized materials with optimized spacer architectures and chemistries specifically engineered to tolerate repeated cleaning cycles.

Ligand Engineering: The Other Half Of Membrane Performance

While surface chemistry determines how ligands are attached, ligand design itself is equally important in defining affinity membrane performance. Separation efficiency depends not only on the number of ligands immobilized but also on whether those ligands present the right binding geometry, accessibility, selectivity, and chemical stability under process conditions.

Our review highlights that conventional ligands such as Protein A remain highly effective for antibody capture, but they are relatively large, costly, and limited in achievable surface density on membrane supports. This has driven growing interest in alternative ligand classes, such as biomimetic small molecules. These ligands may offer advantages such as lower cost, smaller molecular size, improved stability, and/or enhanced selectivity toward emerging therapeutic targets. Ligand architecture also matters. Spacer-arm length, molecular flexibility, and orientation can strongly influence whether target molecules can effectively access binding sites under flow conditions.

Looking ahead, next-generation affinity membranes will likely rely on parallel advances in ligand engineering and surface chemistry. Combinatorial screening, molecular simulation, and structure-guided design are expected to accelerate the discovery of ligands tailored for specific biologics, while improved immobilization methods ensure those ligands are presented in their most effective form.

What The Industry Should Watch Next

Affinity membrane chromatography is increasingly evolving into a chemistry-driven separation platform in which membrane functionalization and ligand engineering can be optimized together.

The companies most likely to succeed with this technology will be those that look beyond membrane format alone and focus on the molecular details of ligand attachment, accessibility, selectivity, and long-term durability. Performance advantages will increasingly come from better engineered interfaces rather than simply higher flow rates.

Several industry trends are likely to shape the next phase of commercial adoption:

Application-specific membrane products

Rather than relying on a universal platform, suppliers are likely to develop dedicated affinity membranes tailored to specific biomolecules such as monoclonal antibodies, viral vectors, recombinant proteins, and emerging therapeutic modalities, each with distinct purification challenges and selectivity requirements.

Lower-cost synthetic ligands

Pressure to reduce purification costs may accelerate the replacement of expensive biologically derived ligands with peptides, aptamers, biomimetic molecules, and other engineered alternatives. Lower separation costs could also help drive broader modernization of legacy purification trains by making it more practical to replace conventional technologies with faster and more flexible membrane-based operations.

Stronger and more reusable membranes

For broader commercial deployment, users will expect membranes that maintain capacity and reproducibility over repeated cleaning/regeneration cycles under realistic manufacturing conditions.

Integration with digital development tools

High-throughput screening, molecular modeling, materials informatics, and data-driven optimization are likely to accelerate both membrane material development and process design, helping shorten timelines for new membrane-ligand platforms from early research to manufacturing implementation.

As biologics pipelines diversify and manufacturers continue to prioritize speed, flexibility, and cost efficiency, well-designed affinity membranes could become an increasingly important tool in modern downstream processing.

About The Authors:

Pengtao Gao is a chemical and environmental engineer specializing in bioseparation and membrane materials. He was a postdoctoral researcher at the Department of Chemical Engineering in KU Leuven, working under the supervision of Professor Xing Yang. His research focuses on downstream purification processes for biopharmaceuticals, particularly the development of high-performance membranes for the selective separation of antibodies and other biomacromolecules. Pengtao obtained his Ph.D. from the same research group in KU Leuven.

Xing Yang is a chemical and environmental engineer and associate professor at KU Leuven in Belgium. She leads the Membrane Engineering for Sustainable Solutions (MEMSuS) lab that works on energy-efficient separation systems, by tailoring separation membrane materials with nano- and micro-structured interfaces, reactive kinetics, and optimal separation units for industrial and pharmaceutical applications. She received her Ph.D. from Nanyang Technological University Singapore.